- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04803006
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in Living Donor Renal Transplantation
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Able to understand the study requirements and provide written informed consent before any study assessment is performed
- Male or female patients ≥ 18 to 65 years of age
- Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor
Key Exclusion Criteria:
- Women of child-bearing potential, unless willing to comply with the use of highly effective methods of contraception as defined by the protocol
- A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
- Recipient with anti-HLA donor-specific antibody (DSA)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression |
Investigational Product |
|
Experimental: Arm 2
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression |
Investigational Product |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Proportion of Patients Off Immunosuppression With Good Safety and Tolerability
Time Frame: 24 months
|
The proportion of patients off immunosuppression with good safety and tolerability at 24 months assessed by immunosuppression dosing; Serum creatinine (estimated glomerular filtration rate [eGFR]); Incidents of Chimeric Transition Syndrome (CTS) and biopsy proven acute rejection (BPAR); Renal biopsy |
24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Incidence of de Novo Donor-specific Antibody
Time Frame: 24 months
|
24 months
|
|
The Incidence of Biopsy Proven Acute Rejection, Death and Graft Loss
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Tracy Killingsworth, Nefro Avillion
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TCD601A201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.